A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin During Metformin Up-titration Compared with Metformin Up-titration Alone in Subjects with Type 2 Diabetes Mellitus - Trial 2015-004224-59
Access comprehensive clinical trial information for 2015-004224-59 through Pure Global AI's free database. This phase not specified trial is sponsored by Merck Sharp & Dohme Corp. and is currently Completed. The study focuses on Type 2 Diabetes mellitus.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2015-004224-59
Completed
Trial Details
EU Clinical Trials Register • 2015-004224-59
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin During Metformin Up-titration Compared with Metformin Up-titration Alone in Subjects with Type 2 Diabetes Mellitus
Study Focus
Sponsor & Location
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Timeline & Enrollment
N/A
N/A
N/A
ICD-10 Classifications
Type 2 diabetes mellitus
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with multiple complications
Data Source
EU Clinical Trials Register
2015-004224-59
Non-Device Trial